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Abstract
To identify biomarkers for glioma growth, invasion and progression, we used a candidate gene approach in mouse models
with two complementary brain tumour phenotypes, developing either slow-growing, diffusely inﬁltrating gliomas or highly
proliferative, non-invasive primitive neural tumours. In a microRNA screen we ﬁrst identiﬁed microRNA-449a as most
signiﬁcantly differentially expressed between these two tumour types. miR-449a has a target dependent effect, inhibiting cell
growth and migration by downregulation of CCND1 and suppressing neural phenotypes by inhibition of G protein coupled-
receptor (GPR) 158. GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the
cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of
glioma, IDH wild-type glioblastoma. The correlation of GPR158 expression with molecular subtypes, patient survival and
therapy response suggests a possible role of GPR158 as prognostic biomarker in human gliomas.
Introduction
The prognostication of human gliomas has seen signiﬁcant
changes over the last 10 years. The identiﬁcation of muta-
tions in two isocitrate dehydrogenase genes, IDH1 and
IDH2, in gliomas [1] was a major discovery, leading to a
biomarker-deﬁned glioma classiﬁcation, IDH and ATRX-
mutant astrocytomas and glioblastomas and IDH-mutant 1p/
19q codeleted oligodendrogliomas [2]. The clinical value of
molecular subtyping of IDH wild-type glioblastoma instead
had limited clinical impact [3, 4]. The only prognostic
biomarker in GBM is the methylation of MGMT but is has
no diagnostic value [5].
To identify additional biomarkers of diagnostic and/or
prognostic value, we used a mouse model of intrinsic brain
tumours generated by Cre-mediated inactivation of Ptenlox/
lox and p53lox/lox genes or of Rblox/lox and p53lox/lox genes in
the neurogenic cell population of the subventricular zone
(SVZ) of the brain, previously in-depth molecularly char-
acterized [6, 7]. Mice with tumours mutant for Pten and p53
(in short Pten/p53) develop diffusely inﬁltrative high grade
gliomas (Fig. 1a) [8–10] with an expression proﬁle of the
TCGA classical GBM [4] or Phillips proneural [11]. Cre-
mediated recombination of the Rb and p53 genes (in short
Rb/p53) in the SVZ, gives rise to poorly differentiated, well-
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demarcated tumours with a primitive neural phenotype and
less frequently also to gliomas (Fig. 1a) [6–8]. These
tumours, previously described as primitive neuroectodermal
tumours (PNET), have an expression proﬁle corresponding
to a malignant childhood tumour, atypical teratoid/rhabdoid
tumour (AT/RT) [6, 12]. We chose to compare these two
models of intrinsic brain tumours with their distinctive








































































































































































































































Fig. 1 Identiﬁcation and validation of miRNAs, differentially expres-
sed (DEmiRs) between glioma and PNET. a Representative histology
of Rb/p53-mutant glioma (left) and PNET (right), and Pten/p53-mutant
glioma (centre). Scale bar corresponds to 1 mm in the upper row
(overview) and 50 µm in the lower row (detail). It shows the inﬁltrative
growth of gliomas (columns 1&2) and the demarcated margins of the
hyper-cellular PNET (column 3). b Heat map of DEmiRs between
Pten/p53-glioma, Rb/p53-glioma, and Rb/p53-PNET (one-way
ANOVA, p < 0.05). Unsupervised clustering analysis was performed
on R. c Venn diagram of DEmiRs between Rb/p53 and Pten/p53-
mutant gliomas. Upregulation indicated with red, and down regulation
with blue arrows next to the miRNAs. d Validation of DEmiRs by RT-
qPCR. In each panel, Rb/p53-PNETs are set as 'calibrator' sample
(orange error bars), and the y-axis represents log2 fold change
(−ΔΔCp) with samples as indicated in the ﬁgure legend. The bars are
means ± s.e.m. (Student’s t-test; *FDR < 0.05; **FDR < 0.01)
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identify mechanisms controlling growth, differentiation and
tumour invasion, and corresponding biomarkers in human
gliomas.
First we set out to discover differentially expressed
micro-RNAs (miRNAs, miR), small non-coding RNAs
regulating gene expression at post-transcriptional level by
binding to the 3′ untranslated region (UTR) of the targeted
mRNA for degradation [13]. miRNAs participate in con-
trolling many biological processes, such as cell cycle,
apoptosis, stem cell differentiation, and immune responses
[14], and they also play a key role in the differentiation and
maintenance of tissue identity [15]. In our screen, miR-449a
was amongst the most signiﬁcantly differentially regulated.
It was selected for subsequent analysis as a tumour sup-
pressive role of miR-449a has been suggested in a number
of malignancies [16–19], most notably in prostate cancer by
targeting classical proto-oncogenes CCND1 [20], c-Myc























































































































































































Inverse correlation of miR-449a and Gpr158
miR-449a targeting Gpr158
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target of E2F1, negatively regulating pRb-E2F1 activity by
CDK6 and CDC25A [23]. A role of miR-449a targeting
MYC-associated zinc ﬁnger proteins has been suggested in
glioblastoma [17]. In contrast, during neural development
miR-449a has a different regulatory role. It is expressed
highest during the proliferative phase of embryonic neuro-
genesis [24] and is essential for the production of inter-
mediate progenitors during cortical development [25, 26].
Amongst the established targets of the miR-449 family are
E2F1, CDK6, CCND1 and BCL2 [20, 23, 27]. miR-449a
targets a site in the 3′ UTR of the CCND1 transcript, and
miR-449a signiﬁcantly reduces Cyclin D1 protein in PC-3
cells [20]. Here, we identify a new target of miR-449a, the
G-protein coupled receptor 158 (GPR158), a member of a
large group of cell surface proteins exerting a range of
diverse cellular functions. GPR158 and two others, GPR156
and GPR179 belong into the gamma-aminobutyric acid
receptor branch of the GPCR glutamate family (Group III),
containing 7 orphan receptors [28]. The ﬁrst identiﬁed roles
of GPR158 were those of a plasma membrane scaffold
protein in retinal bipolar neurons and [29], and the
expression in trabecular meshwork cells in the eye’s aqu-
eous outﬂow pathways, contributing to the pathophysiology
of steroid-induced ocular hypertension and glaucoma [30].
It has relevance to prostate cancer growth and progression
[31], and a role in lung cancer outcome was identiﬁed [32],
thus presenting a potential relevant link to our ﬁndings in
brain tumours. Here we show a target dependent effect of
miR-449a, inhibiting growth and migration by down-
regulating CCND1 and suppressing neural differentiation
by inhibiting GPR158. In human gliomas, high levels of
miR-449a and low expression of GPR158 are associated
with higher malignancy and poorer survival.
Results
miR-449a is signiﬁcantly differentially expressed
between experimental gliomas and primitive neural
tumours
To identify genes that are differentially expressed (DE)
between gliomas and PNET (Fig. 1a) we performed miRNA
microarrays. Unsupervised hierarchical clustering identiﬁed
89 differentially expressed miRNAs (DE-miRs) between
gliomas of both genotypes (Pten/p53 and Rb/p53), and
PNET’s (Rb/p53) (Fig. 1b, Supplementary Table 1). Twenty
miRs were differentially expressed between gliomas (Pten/
p53) and PNETs (Rb/p53) (Supplementary Table 1).
Twenty-six signiﬁcantly DE-miRs were identiﬁed between
gliomas (Pten/p53) and PNETs (Rb/p53), and 21 top DE-
miRs between Rb/p53 glioma and PNETs (Fig. 1c). We
found a high degree of overlap with 16 miRNAs co-existing
in both DE-miR groups. Reverse transcription (RT)-quan-
titative PCR (RT-qPCR) reduced the group to 9 DE-miRs
between gliomas and PNETs (Fig. 1d; Supplementary Table
1), and of those, miR-449a was most signiﬁcantly differ-
entially expressed (Fig. 1d). Gene ontology analysis of
these nine miRNAs showed an association with neurogen-
esis and cell migration (Supplementary Table 2). miR-449a
is enriched in astrocytes [33], whereas miR-219 and miR-
338 are essential for oligodendrocyte differentiation [15].
Considering that miR-449a is involved in the regulatory
network of RB and P53 [23, 34], it was a promising can-
didate and most likely relevant to the brain tumour
phenotype.
miR-449a directly targets Ccnd1 and Gpr158
miR-449a targets were identiﬁed with TargetScan 7.1,
resulting in a list of 101 putative targets with conserved
binding sites (Fig. 2a; Supplementary Table 1). To identify
DE genes between the two tumour types, we retrieved the
top 1000 DE-genes ranked by logarithmic fold change
(glioma/PNET) from our published Exon Microarray data-
set (GSE42515), and matched them against the 101 putative
Fig. 2 Identiﬁcation of Gpr158 as a direct target of miR-449a. a Venn
diagram with eight candidate genes emanating from 101 in silico
putative targets and 1000 down-regulated genes in experimental
PNETs compared with gliomas by analysis of exon expression array. b
Candidate gene expression level is validated by RT-qPCR in Rb/p53
(orange error bars), Rb/p53ant (red bars) and Pten/p53 cells (grey bars).
Most differentially expressed Ccnd1 and Gpr158 are further analysed,
as their expression is similar in Rb/p53ant and Pten/p53 cells, but
signiﬁcantly higher than in Rb/p53 cells. c IHC staining shows that
Gpr158 expression is minimal in miR-449 highly expressing PNETs,
but strong in miR-449 low expressing gliomas. Scale bar 50 µm. d
Schematic illustration of Ago2 and biotin double pull-down assay for
assessment of miRNA-mRNA binding. Commercial synthetic miR-
449a mimics are transfected into neural stem cells, and Ago2 immu-
noprecipitation is carried out to conﬁrm that miRNA-mRNA binding
is RISC dependent. Fraction 1 represents the input RNA, fraction 2 the
Ago2 depleted fraction, i.e, miRNA and mRNA unbound to Ago2.
Fraction 3 represents miRNA449a-mRNA complex bound to Ago2,
representing the degradation complex RISC. These fractions were then
tested for the enrichment of Gpr158 and Ccnd1 transcripts: e
Enrichment of Ccnd1 and Gpr158 is measured after pull-down using
RT-qPCR. The x axis shows the fraction as described in (d). There is a
highly signiﬁcant enrichment in fraction 3 (Ago2-dependent miR-449a
–Gpr158 complex) indicating direct interaction. f miR-449a binding
sequence in the 3′ UTR of Gpr158. A mutation of the 3’UTR of
Gpr158 generated in the site complementary to the seed region of
miR-449a. *Indicates the mutant nucleotides. g miR-449a directly
targets Gpr158 by interacting with its 3′ UTR. Relative luciferase
activity (normalized to control) of BTSCs transfected with pMIR-
Gpr158-3′ UTR-wt or pMIR-Gpr158-3′ UTR-mut, and co-transfected
with miRNA negative control or miR-449a mimics. This suggests a
signiﬁcant miR-449a mediated downregulation of Gpr158, which is
not seen in the mutant control. All ﬁgures: *p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001; ****p ≤ 0.0001 (Student’s t-test). Each bar represents
mean ± sd












































































































































































































Fig. 3 miR-449a inhibits cell proliferation and migration of BTSC
in vitro. a Analysis of the stem cell frequency of Pten/p53 and Rb/p53
BTSCs using the extreme limiting dilution assay. Negative wells were
counted 7 days post-seeding. Frequency of sphere-forming cells: Pten/
p53: 1/4.96; Rb/p53: 1/8.32, n= 12, p= 0.065, indicating lower rate
of self-renewal of Rb/p53 cells. b High levels of miR-449a in Rb/p53
mBTSC compared to Pten/p53 BTSC (p < 0.001), normalized for
Pten/p53. c miR-449a reduces cell proliferation (conﬂuence assay):
Pten/p53 (miR-449alow) BTSC grow faster than Rb/p53 (miR-449ahigh)
mBTSC. Treatment of Pten/p53 BTSCs with miR-449a mimic reduces
their proliferation, whilst antagomir-treated Rb/p53 (Rb/p53ant) BTSC
show increased proliferation, compared to scrambled-treated controls,
respectively. d The gap closure assay shows the cell migration over
12 h into an artiﬁcially generated cell-free space. miR-449alow cells
(i.e. Rb/p53ant and Pten/p53scramble) migrate faster and almost close the
gap after 12 h; whereas miR-449ahigh cells (i.e., Rb/p53scramble and
Pten/p53mimics) hardly advance into the gap. Recording of multiple
time points during the 12 h period visualizes the dynamics of migra-
tion and conﬁrms a statistically signiﬁcant difference in the live cell
imaging assay (right ﬁgure part). e Quantiﬁcation of the invasion of a
mass of 5000 cells into 3D collagen. The left ﬁgure part shows an
example of the outgrowth of processes from spheres. miR-449alow
cells (i.e., Rb/p53ant (top right) and Pten/p53scramble (bottom left)) show
substantial outgrowth into the matrix. In contrast, miR-449ahigh cells
(i.e., Rb/p53scramble (top left) and Pten/p53mimics (bottom right)) hardly
advance into the matrix (left panel). The right ﬁgure part shows
quantiﬁcation with Image J, conﬁrming the statistically signiﬁcant
difference (n= 12). f RT-qPCR analysis of differentiation markers in
BTSC shows a proneural gene expression pattern in Pten/p53 and in
antagomir-treated Rb/p53 BTSCs compared to the baseline of
untreated Rb/p53 BTSC (orange error bars). Inhibition of miR-449a
(i.e., Rb/p53ant, red bars) resulted in the shift of basal expression proﬁle
of Rb/p53 cells towards that of Pten/p53 BTSCs (grey bars)
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targets, following permissive ﬁltration criteria: (i) miR-449a
is highly expressed in PNETs, expecting downregulated
targets; (ii) DE-genes with p > 0.05 were also considered to
minimize false negative calls. Eight genes were selected
(Notch1, Met, Gnao1, Meto1, Gpr158, Parp8, Ccnd1 and
St8sia3) (Fig. 2a,b). To identify candidates regulated by
miR-449a, we analysed Rb/p53 (miR-449ahigh), Pten/p53
(miR-449alow), and Rb/p53antagomir mBTSCs (miR-449alow),
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and selected those targets which were upregulated in miR-
449alow mBTSCs. Quantiﬁcation conﬁrmed that only
Gpr158 and Ccnd1, but not the other six genes, were cor-
respondingly regulated in both Pten/p53 and Rb/p53antagomir
cells, compared to the baseline of Rb/p53 cells (Fig. 2b).
Ccnd1 and Gpr158 carry conserved miR-449a binding sites
within their 3′ UTR [20], (Fig. 2f). In keeping, primary Rb/
p53 brain tumours (PNET) express low, and Pten/p53
gliomas high Gpr158 levels (Fig. 2c).
We then conﬁrmed a functional link between miR-449a
and its target Gpr158 by two functionally independent
approaches: a modiﬁed hybrid Argonaute 2 (AGO2) pull-
down assay and a luciferase reporter assay. The AGO2
assay [35, 36] (Fig. 2d) uses an established miR-449a
target, CCND1, as positive control [20]. After double pull-
downs of AGO2 and biotin-labelled miR-449a mimics in
tandem, the relative enrichment of each fragment compared
to input RNA was measured by RT-qPCR (Fig. 2e, number
corresponds to the fraction in Fig. 2d). We conﬁrmed that
the degradation of Gpr158 mRNA by miR-449a was
dependent of RNA-induced silencing complex [37] (Fig.
2e), demonstrating direct regulation of Gpr158 expression
by miR-449a. The luciferase assay conﬁrmed physical
binding of miR-449a to the Gpr158 3′ UTR and to locate
the conserved binding sequence within the 3′ UTR of
Gpr158. Luciferase reporter plasmids containing wild-type
(pMIR-Gpr158-3′ UTR-wt) and mutant (pMIR-Gpr158-3′
UTR-mut) sequence complementary to the seed region of
miR-449a were generated (Fig. 2f). Mir-449a mimics sig-
niﬁcantly reduced luciferase activity under a wild-type 3′
UTR (p < 0.001), which was rescued by substituting the
reporter plasmid with a mutant seed sequence (Fig. 2g),
indicating that the mutated 3′ UTR of Gpr158 reduced miR-
449a binding.
miR-449a inhibits brain tumour stem cell self-
renewal, proliferation and migration in vitro
To characterize the role of miR-449a in brain tumour stem
cells (BTSC), murine (m)BTSC were derived from SVZ
stem/progenitor cells of naïve Pten/p53 or Rb/p53 mice,
recombined in vitro [7] and expanded in EGF and FGF-
enriched serum-free stem cell medium [38]. An in vitro
extreme limiting dilution assay [39] showed a tendency (p
= 0.065) of reduced self-renewal of Rb/p53 BTSC (miR-
449ahigh), compared to Pten/p53 cells (miR-449alow) (Figs.
3a, b). In a proliferation assay, Pten/p53 cells grew faster
(Fig. 3c) and in a gap closure assay they moved faster than
Rb/p53 cells into an artiﬁcially introduced gap (Fig. 3d). To
test if these were miR-449a-mediated effects, miR-449a
antagomir or mimics were introduced into mBTSCs. Tran-
sient inhibition of miR-449a with antagomir in Rb/p53
mBTSCs signiﬁcantly increased their proliferation and
migration, consistent with previous reports in cell lines
derived from hepatocellular carcinoma [16], colon cancer
[27], or prostate cancer [22], whilst the opposite effect was
seen when a miR-449a mimic was introduced into Pten/p53
cells (Figs. 3c, d). In a 3D collagen matrix tumour invasion
assay, inhibition of miR-449a expression in Rb/p53 cells
increased cell migration, whereas miR-449 mimics in Pten/
p53 cells slowed down migration (Fig. 3e), consistent with
ﬁndings in hepatocellular carcinoma cells [16]. In conclu-
sion, in stem cell medium, miR-449ahigh mBTSC grow
slower than miR-449alow mBTSC, suggesting a suppressive
role of miR-449a on proliferation, migration and invasion.
Fig. 4 miR-449a reduces cell proliferation and migration by sup-
pressing Ccnd1, and neural phenotypes and apoptosis by suppressing
GPR158 in mBTSC. a miR-449a reduces Ccnd1 levels in mBTSC:
miR-449a antagomir (ant) treatment of mi449ahigh Rb/p53 mBTSC
restores Ccnd1 expression, and conversely miR-449a mimic (mim)
treatment of Pten/p53 miR-449alow mBTSC reduces Ccnd1 expres-
sion. Scr= scramble (b) Transient transfection of Rb/p53 mBTSC
with a Ccnd1 expression vector results in twofold overexpression of
Ccnd1 and increased cell proliferation, and c knockdown decreases it.
d Forced Ccnd1 overexpression (transfection) antagonises miR-449a
-mediated inhibition of cell proliferation. Top curve (grey) baseline
Pten/p53 (miR-449alow), bottom curve miR-449a knockdown, and
middle curve miR-449a kd+ Ccnd1 restore. e Ccnd1 accelerates cell
proliferation in a conﬂuence assay: Pten/p53 cells (grey) grow faster
than Rb/p53 cells (orange). Ccnd1 overexpression increases pro-
liferation of Rb/p53 cells (red) which now proliferate faster than Pten/
p53 cells. These grow slower than untransfected cells Rb/p53 cells
(orange) when Ccnd1 is inhibited (black). f Inhibition of Ccnd1
reduces outgrowth of tumour sphere processes, demonstrating the role
of Ccnd1 in cell proliferation and migration. G-S, effects of over-
expression or inhibition of Gpr158 in Rb/p53 or Pten/p53 mBTSC (g)
Gpr158 levels in naïve and Gpr158 transfected Rb/p53 or Pten/p53
mBTSC. h Gpr158 downregulates cell proliferation, i cell migration
and j self-renewal proportionally in Rb/p53 or Pten/p53 mBTSC. A 2-
fold decrease of tumour sphere forming cells was observed upon
Gpr158 overexpression. BTSCs stably expressing Gpr158= 1/6;
BTSCs control= 1/3; i.e., requiring the presence of 3 cells to form 1
neurosphere in controls, vs. 6 cells to form a sphere in Gpr158 over-
expressors (p= 0.02) n= 12; p= 0.02. k Suspension culture of
mBTSCs in serum-free medium. Upon stable expression of Gpr158,
mBTSC attach to the surface of the cell culture well, change mor-
phology and involute/grow slower. l The Caspase-3/7 activity assay
indicates that Gpr158 signiﬁcantly increases apoptosis in mBTSC. m
Knock-down of Gpr158 using siRNA in mouse BTSCs, conﬁrmation
of abolition of Gpr158 mRNA expression. Down-regulation of
Gpr158 promotes cell proliferation (n), migration (o) and tumour
sphere forming ability (p). q Stable expression of Gpr158 signiﬁcantly
upregulates expression of neural genes, assessed in a mouse neuro-
genesis qPCR proﬁler array, while siRNA knock-down of Gpr158
signiﬁcantly reduces the expression of Map2, Sox2 and Pdgfra. r
Stable knock-down of GPR158 in three human GBM primary cell
lines cultured in serum-free medium, containing hBTSC reduces
BTSC apoptosis. s Overexpression of GPR158 signiﬁcantly increases
apoptosis of human GBM primary cells (hBTSC). All ﬁgures: *p ≤
0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 (Student’s t-test). Each
assay was performed at least twice
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miR-449a targets Ccnd1, inhibiting proliferation and
migration of BTSC in vitro
First we conﬁrmed the known effect of miR-449a to
downregulate Ccnd1. In keeping, treatment of Rb/p53
mBTSC (miR-449ahigh) with miR-449a antagomir rescued
(i.e., increased) Ccnd1 expression, whilst treatment of Pten/
p53 mBTSC (miR-449alow) with miR-449a mimic reduced
Ccnd1 expression (Fig. 4a). This effect can be antagonised
by overexpressing Ccnd1 in Rb/p53 mBTSC, increasing
proliferation (Fig. 4b), or by Ccnd1 siRNA treatment of
Pten/p53 mBTSC, reducing proliferation (Fig. 4c), con-
sistent with previous reports [27]. Co-transfection of Pten/
p53 mBTSC with mir-449a mimic and Ccnd1 expression
vector restored the reduced proliferation of cells treated with
mir-449a mimic alone (Fig. 4d). Likewise Ccnd1 over-
expression increases migration of Rb/p53 cells, and inver-
sely inhibition in Pten/p53 cells inhibits cell migration in a
gap closure assay (Fig. 4e). In keeping the ability of Pten/
p53 (miR-449alow; Ccnd1high) mBTSC to invade a matrigel
matrix is antagonised by Ccnd1 shRNA (Fig. 4f).
The miR-449a target Gpr158 promotes
differentiation and apoptosis, and inhibits
proliferation and migration of BTSC in vitro
Next we characterized the effects of miR-449a action on
Gpr158 in vitro (Fig. 4). Expression levels of GPR158 are
highest in murine neural stem/precursors cells (mNSPC),
lower in Pten/p53 and virtually undetectable in Rb/p53
mBTSC (Supplementary ﬁgure 1A). Unexpectedly, over-
expression of Gpr158 in Rb/p53 and Pten/p53 mBTSC,
resulted in slower growth of both cell lines, whereby Pten/
p53 cells always proliferated and migrated faster than Rb/
p53 cells (Figs. 4g-i), i.e., Gpr158 further reduces pro-
liferation and migration. This is seemingly incompatible
with the ﬁnding that miR-449a inhibits Gpr158, as both
miR-449ahigh Rb/p53 and miR-449alow Pten/p53 cells show
further reduction of proliferation, i.e., in the same direction
as miR-449a treatment. However, when we explored if
Gpr158 regulates the ability of BTSC to form tumour
spheres, we found in an extreme limiting dilution assay [39]
a signiﬁcant reduction of sphere forming cells upon Gpr158
overexpression (Fig. 4j). Gpr158 overexpressing BTSC
were smaller and tended to attach and differentiate (Fig. 4k),
suggesting a role of Gpr158 to induce neural differentiation,
and the potential to override miR-449a effects. Indeed
siRNA knock-down of Gpr158 in naïve, adherently grow-
ing murine neural stem/progenitor cells (mNSPC) (Sup-
plementary Figure 1B) showed global reduction of
expression levels of the majority of genes associated with
neural differentiation/neurogenesis (Supplementary Figure
1C), of which Nrp1, S100α6 and Tnr were signiﬁcant.
Knockdown of Gpr158 in Pten/p53 mBTSCs (Fig. 4m)
increases cell migration (Fig. 4o), and sphere formation
(Fig. 4p). The role of GPR158 to induce neural marker
expression, was quantiﬁed in a qRT-PCR proﬁler assay.
There is signiﬁcant up-regulation of the proneural markers
Map2, Sox2, and Pdgfra [4], and of three extracellular
matrix-associated genes Filamin A (Flna), Netrin 1 (Ntn1),
and Pleiotrophin (Ptn), and downregulation upon Gpr158
knock-down (Fig. 4q).
Neural differentiation of stem and progenitor cells is
associated with apoptotic cell death [40], and in keeping,
overexpression of Gpr158 in mBTSC resulted in signiﬁcant
induction of caspase-3/7 activities (Fig. 4l), whilst Gpr158
siRNA knockdown increased proliferation (p < 0.05, Figs.
4m, n), and migration (Fig. 4o), and there was increased
sphere formation (Fig. 4p). Consistent with this observation,
also GPR158 knockdown in three human GBM primary
cultures signiﬁcantly reduced apoptosis (Fig. 4r), and in
keeping, overexpression of GPR158 in two human GBM
primary cultures induced apoptosis (Fig. 4s). Baseline levels
of a selection of glioma cell lines is shown in Supplemen-
tary Figure 3G.
In conclusion, increase of GPR158 expression in
mBTSC and hBTSC reduces proliferation, migration and
cancer stem cell formation, upregulation of proneural mar-
kers and induction of apoptosis whilst downregulation of
GPR158 has the opposite effect. We identiﬁed that miR-
449a has distinct, target-dependent (i.e., CCND1 and
GPR158) effects on cellular growth, migration and
differentiation.
BTSC differentiation induced by GPR158 is
antagonised by miR-449a
Under growth-promoting conditions in EGF, FGF enriched
serum-free medium, miR-449a suppresses Ccnd1 and
inhibits migration and invasion, suggestive of a tumour-
suppressive effect. This effect is seen in cell lines derived
from somatic cancers, such as non-small lung cancer [18],
hepatocellular carcinoma [16], colon cancer [27] or neuro-
blastoma [19]. A different role of miR-449a emerges from
studies on CNS development where high miR-449a levels
are associated with neural progenitor expansion and sup-
pression of neural differentiation [25, 26], possibly through
an inhibition of GPR158. Therefore, we ﬁrst determined
Gpr158 and Ccnd1 expression in Pten/p53 or Rb/p53
mBTSC, under proliferative (serum-free, EGF, FGF enri-
ched) and differentiating (3% FBS) conditions. Immuno-
ﬂuorescent labelling for Gpr158 shows virtually no
labelling under proliferative conditions (Fig. 5a) and upre-
gulation when grown in differentiating conditions, whilst
density of nuclear labelling for Ccnd1 markedly decreased
upon culturing under differentiation conditions.
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Quantiﬁcation conﬁrms upregulation of Gpr158 and
downregulation of miR-449a upon induction of neural dif-
ferentiation (Fig. 5a). Next we investigated the effect of
miR-449a on neural differentiation on individual cellular
level, again comparing serum-free, EGF and FGF-enriched
growth-promoting environment with differentiation-
inducing culture conditions containing foetal bovine
serum (FBS) (Fig. 5c). Gpr158 overexpression in Pten/p53
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or Rb/p53 mBTSC induces neural differentiation, demon-
strated by the detection of doublecortin (DCX), a protein
expressed in migrating neuroblasts and immature neurons
[41]. Immunolabelling for DCX in lentivirus-Gpr158
transduced Rb/p53 mBTSC conﬁrms expression (Fig. 5b)
and qPCR proﬁler expression analysis of these cells shows
upregulation of genes associated with proneural signature
Rb/p53 mBTSC (miR-449ahigh). Dual immunoﬂuorescence
of Pten/p53 or Rb/p53 mBTSC, for GFAP and DCX shows
virtually no positive cells in EGF, FGF-enriched serum-free
medium even with miR-449a antagomir transfection or
GPR158 transduction (Fig. 5c,d). Induction of the cells with
3% FBS marginally increases GFAP and DCX positive
cells in Rb/p53 mBTSC and much stronger in Pten/p53
cells, consistent with the different baseline levels of miR-
449a in the two mBTSC lines (Figs. 5c2, d2, E, F). How-
ever, Rb/p53 (miR-449ahigh) mBTSC transfected with miR-
449a antagomir rescues the suppression of neural differ-
entiation, and in keeping, Pten/p53 (miR-449alow) mBTSC
transfected with miR-449a mimic (Fig. 5d4) showed a
marked reduction compared to empty vector-transfected
controls (Fig. 5d2). Cells spared from transfection with
miR-449a mimic (Fig. 5d4) conspicuously retained their
expression of DCX, suggesting a direct effect of miR-449a
to suppress neural differentiation. The same effect is seen
when Gpr158 expression was inhibited with Gpr158
siRNA. Furthermore, we conﬁrm these effects when cells
were subjected to induction of neuronal (retinoic acid and
forskolin) and glial differentiation (LIF/BMP2) (Supple-
mentary Figure 2). Here, glial and neuronal differentiation
was seen after suppression of miR-449a expression with
antagomir (Supplementary Figure 2F, G, O) or over-
expression of Gpr158 (Supplementary Figure 2H, J, P, R).
An inverse experimental setup was chosen for Pten/p53
mBTSC (miR-449alow) (Supplementary Figure 2B-D, and
K-M), conﬁrmed by cell quantiﬁcation (Supplementary
Figure 2I, J, Q, R).
In conclusion, the neurogenic effect of Gpr158 can be
antagonised by mir-449a. This effect is modulated by
growth conditions, whereby a proliferation-inducing envir-
onment with EGF, FGF-enriched serum-free medium is not
permissible neurogenic effects of GPR158. Under these
conditions, downregulation of Ccnd1 explains the miR-
449a-induced reduction of growth and migration. Instead, in
an environment permissive for neural differentiation, miR-
449a and Gpr158 are antagonists where miR-449a inhibits,
and Gpr158 promotes neural phenotypes.
miR-449a downregulates Gpr158 and Ccnd1 in
allografts in vivo
We further conﬁrmed the interaction of miR-449a with
Ccnd1 and Gpr158 in vivo. Allografts of Rb/p53 (miR-
449ahigh), Pten/p53 (miR-449alow), and Rb/p53ant (miR-
449alow) were generated in NOD-SCID immunodeﬁcient
mice. Pten/p53 allografts have a (pro)-neural phenotype and
diffusely inﬁltrate the CNS. Rb/p53 allografts are poorly
differentiated, lacking distinctive glial and neural marker
expression and grow sharply demarcated against the CNS
(Fig. 6a, arrowheads). Rb/p53ant grafts reverted to an inﬁl-
trative phenotype (Fig. 6b arrowheads), similar to Pten/p53
allografts (Fig. 6c). Quantiﬁcation of expression on immu-
nolabelled tissue sections with whole slide imaging and
image analysis [6] corroborates the RNA expression data of
Pten/p53 and Rb/p53ant tumours with their high expression
of Olig2, PDGFRα and Sox2, whilst Rb/p53 grafts
expressed much lower levels of these markers with quan-
tiﬁcation data in the right column (Figs. 6g, k, o, s). miR-
449a targets CCND1 and Gpr158 are highly expressed in
tumours with low miR-449a levels (i.e., in Pten/p53 and Rb/
p53ant) whilst it is much less expressed in Rb/p53 (miR-
449ahigh) tumours, consistent with the in vitro experiments
(Fig. 5). In conclusion, miR-449a directly downregulates
Gpr158 and Ccnd1 in vivo (Figs. 6t, x), reducing neural
phenotypes.
Fig. 5 miR-449a antagonises Gpr158-induced neural differentiation. a
Induction of neural differentiation with 3% FBS increases Gpr158 and
reduces miR-449a expression. Ccnd1 expression in EGF, FGF-
enriched stem cell medium (upper part) is suppressed in miR-
449ahigh Rb/p53 with fewer nuclei labelled, and the overall expression
is strongly reduces upon growth in 3% FBS supplemented medium.
Quantiﬁcation of miR-449a and Gpr158 expression in these cells on
the right. b Stable overexpression of Gpr158 antagonises miR-449a
and promotes neural differentiation in miR-449ahigh Rb/p53 mBTSC.
Upper panel, cells transformed with lentivirus expressing GFP or an
Gpr158 expressing lentivirus, stained for doublecortin to label post-
mitotic neural progenitor cells and early immature neurons in serum-
free, EGF and FGF enriched stem cell medium. RT-PCR proﬁling
shows expression of 'proneural' and downregulation of 'mesenchymal'
genes upon Gpr158 expression (c) Knock-down of miR-449a or
overexpression Gpr158 induce glial and neural marker expression. Rb/
p53 mBTSC (miR-449ahigh), were either transfected with vehicle
(pcDNA 3.1+, c1), miR-449a antagomir (GFP labelled, c3) or the
lentivirus pLX301-Gpr158 (c5). Following exposure to 3% FBS for
48 h (right panel, c2, 4, 6), only miR-449alow cells (c4) or increase of
GPR158 levels (b6) but not vector-only transfected controls (b2) show
increased GFAP and DCX positive mBTSC. d The opposite result is
seen with Pten/p53 mBTSC (miR-449alow) are treated with miR-449a
mimic or Gpr158 siRNA. In EGF, FGF enriched, serum free medium
only rare DCX positive mBTSC are seen (d1). Exposure to 3%FBS
enriches in GFAP or DCX expressing mBTSC (d2). Transfection with
GFP labelled miR-449a (d3, 4) mimic greatly reduces the number of
GFAP and DCX positive cells in 3% FBS enriched medium (d4),
compared to d2. The DCX labelled differentiated mBTSC (d4 inset)
was spared from (GFP labelled) miR-449a mimic. In keeping,
knockdown of Gpr158 abolishes GFAP and DCX expression on
mBTSC (c6). e quantiﬁcation of DCX (red bars) and GFAP (green
bars) positive cells in miR-449a antagomir or GPR158 overexpressing
Pten/p53 mBTSC. E, quantiﬁcation of DCX (red bars) and GFAP
(green bars) positive cells in miR-449a mimic or GPR158 knock-down
Rb/p53 mBTSC
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Fig. 6 Expression of neural
markers, Gpr158 and Ccnd1 in
allografts of miR-449ahigh and
miR-449alow tumours.
Phenotype of tumours generated
from allografted Rb/p53 (left
column), miR-449a antagomir-
treated Rb/p53ant (centre
column) and Pten/p53 cells
(right column) into NOD-SCID
mice. a Morphology (H&E)
shows a well demarcated tumour
border in Rb/p53 PNET (single
line of arrowheads), and an
inﬁltrative margin in both,
antagomir-treated Rb/p53 grafts
(b) and Pten/p53 grafts (c).
Image analysis of regions of
interest on whole slide digitized
images of immunostained
histological sections with
Deﬁniens Developer shows a
reversal of Rb/p53ant grafts to
levels found in Pten/p53 grafts
(markers Olig2 (d–g), Pdgfrα
(l–o), and Sox2 (p-s), whilst
only DCX it is unaltered (h–K).
Expression of these markers is
reduced in Rb/p53; miR-449ahigh
tumours, high in Pten/p53 (miR-
449alow) grafts, and restored
upon suppression of miR-449a
in antagomir-treated Rb/p53ant;
miR-449alow grafts. (t-ae) miR-
449a regulates Ccnd1 and
GPR158 in tumours in vivo:
(t–w), Ccnd1 expression is low
in Rb/p53 (miR-449ahigh)
tumours (t), and high in Pten/
p53 (miR-449alow) tumours (u)
as well in antagomir-treated Rb/
p53; miR-449alow tumours (v,
w). Gpr158 expression is
regulated correspondingly (x–
aa). In keeping with the shorter
survival of mice with Rb/p53;
miR-449ahigh tumours,
proliferation is high in these
tumours (ab). Scale bar 50 µm.
All ﬁgures: *p ≤ 0.05; **p ≤
0.01; ***p ≤ 0.001 (Student’s t-
test). Each value represents the
mean ± s.d
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GPR158 is highly expressed in the human CNS, and
differentially expressed in human
oligodendrogliomas, astrocytomas and
glioblastomas
To establish the roles of miR-449a and GPR158 in human
gliomas, we ﬁrst analysed 'RNA-Seq by Expectation-Max-
imization' (rsem) data of 431 gliomas (155 GBM and 276
low-grade gliomas (LGG), Supplementary table 3) from the
TCGA database, and complemented this dataset with
mRNA expression analysis and immunohistochemical
detection of GPR158 protein in human gliomas from our
institution (NHNN, Supplementary table 3). To correlate
GPR158 expression with clinically, diagnostically and
biologically relevant tumour entities [2], we deﬁned oligo-
dendrogliomas (O, n= 83) as IDH mutant, 1p/19q co-
deleted tumours, and astrocytomas (A, n= 138) as IDH
mutant, ATRX mutant tumours with no 1p/19q codeletion.
As the WHO grade is of disputed clinical signiﬁcance [42,
43] in astrocytomas, we did not further stratify these
tumours by WHO grades II or III. IDH mutant GBM
(GBM-IDH, n= 9) which carry a poorer prognosis than
IDH mutant astrocytomas, were grouped separately from
astrocytomas. IDH wild-type high grade gliomas with 7p
gain, 10q loss, EGFR ampliﬁcation and TERT promoter
mutation were considered as GBM (corresponding to WHO
grade IV) (n= 146). Histological lower grade IDH wild
type astrocytomas with molecular proﬁles of glioblastoma
are considered as 'early stage' GBM [44] (eGBM; n= 54).
Using these criteria and TCGA RNA sequencing data, we
investigated GPR158 expression in these glioma subtypes.
GPR158 expression was highest in the CNS (n= 5) and in
oligodendrogliomas, followed by astrocytomas (p <
0.0001), and signiﬁcantly lower in eGBM and GBM (p <
0.0001; Fig. 7a, Supplementary Figure 3A-C). The differ-
ence of GPR158 expression levels was statistically sig-
niﬁcant between eGBM and GBM (p < 0.0001), suggesting
that GPR158 was further down-regulated upon tumour
progression to a higher (histological) grade. In 29 other
TCGA tumour entities (Supplementary Figure 3D), with the
exception of pheochromocytoma and paraganglioma [45],
the remaining tumours types expressed very little or no
GPR158. In conclusion, we show here that there is a sta-
tistically signiﬁcant difference of GPR158 expression
between clinically and biologically distinct glioma sub-
groups, and GPR158 expression was speciﬁc in nervous
system-related tumours. mRNA expression data of miR-
449a and GPR158 were conﬁrmed on 25 frozen glioma
samples and 5 CNS samples from our own collection (miR-
449a: CNS, n= 5; O, n= 7; A, n= 7; GBM, n= 8; and
GPR158 CNS, n= 5; O, n= 8; A/GBM-IDH, n= 8; GBM,
n= 9) (Figs. 7b, c) by RT-qPCR analysis. miR-449a
inversely correlates with GPR158 expression (Figs. 7b, c,
d), consistent with previous experiments. To assess, if the
expression of the miR-449a target CCND1 may also cor-
relate with tumour grade and type, we retrieved expression
data from TCGA. CCND1 rsem is low in CNS tissue, and
slightly increased within a wide range of expression levels
across all subgroups of gliomas, with no statistically sig-
niﬁcant difference between oligodendrogliomas, astro-
cytomas and IDH wild-type glioblastoma (Figs. 7e, f).
Thus, the expression of CCND1 remains largely indepen-
dent of the tumour subtypes, supporting the notion that
GPR158 may have a role as biomarker that is independent
from the miR-449a target CCND1.
Fig. 7 Analysis of GPR158 expression in tumour and control brain
samples. Expression of GPR158 in CNS, and the ﬁve glioma sub-
groups oligodendroglioma, astrocytoma, GBM-IDH, early GBM and
GBM, as deﬁned by the integrated (morphological and molecular)
diagnosis. a TCGA RNA sequencing (rsem) data indicate highest
GPR158 expression in CNS (n= 5) and oligodendrogliomas (O, n=
84), a reduction in astrocytomas (A, n= 138), GBM-IDH (n= 9), and
further down-regulation in 'early GBMs' (n= 54) and GBMs (n=
148). The differences between O, A/GBM-IDH, early-GBM and GBM
(both IDHwt) are highly signiﬁcant. (b) GPR158 RNA expression in
frozen CNS and glioma tissue from our institution. Relative GPR158
expression levels measured by RT-qPCR is consistent with TCGA
rsem data. c Expression levels of miR-449a in the same samples, and
(d) plot of inverse correlation of miR-449a and GPR158 RNA
expression levels. e CCND1 expression is higher in gliomas than in
CNS but not signiﬁcantly differentially expressed across all glioma
groups in TGCA samples. f in our samples, CCND1 expression is
lower in GBM than in oligodendrogliomas, in keeping with the
observation in our brain tumour allografts (Figs. 6t, u, v) that the
proliferative Rb/p53 tumours downregulate Ccdn1. g Representative
histology and immunostaining patterns in tumours (n= 93) from our
institution. GPR158 immunoreactivity is strong in CNS and oligo-
dendroglioma, much weaker in astrocytoma, and nearly negative in
IDH wild-type 'early' GBM and GBM. Mutant IDH1 is expressed in
oligodendrogliomas and astrocytomas, but not in CNS, and glio-
blastomas. ATRX is lost only in IDH mutant astrocytomas. All other
tumours and the CNS maintain ATRX expression. Scale bar corre-
sponds to 100 µm. h Quantiﬁcation of protein expression by whole
slide imaging and image analysis of tissue sections immunostained for
GPR158. CNS tissue shows the highest expression, followed by oli-
godendrogliomas and astrocytomas, whilst there is a signiﬁcantly
lower expression in IDH wild-type early-GBM and GBM, consistent
with the RNA expression data shown in (a and b). Oligodendroglioma
(n= 17), astrocytoma (n= 16), early-GBM (n= 12) and GBM (n=
34). CNS tissue data were obtained from tissue fragments within some
of the resection specimens containing normal CNS. i Overview and
summary of demographic parameters, tumour grade, integrated diag-
nosis and molecular proﬁle of the tumours analysed in (e). There are
two types of IDH mutant gliomas, oligodendrogliomas, deﬁned by a
loss of chromosomal arms 1p and 19q (1p/19q codeleted) and typically
with a mutation in the telomerase reverse transcriptase (TERT) pro-
moter, and astrocytomas or glioblastomas (GBM) which carry a
mutation of alpha thalassemia/mental retardation syndrome X-linked
(ATRX) resulting in functional loss of the protein. Patients with IDH
mutant tumours are younger than those with IDH wild-type GBM.
GPR158 levels are highest in oligodendrogliomas, lower in astro-
cytomas and lowest in GBM, as described above
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To conﬁrm GPR158 protein expression on parafﬁn-
embedded tissue sections by immunohistochemical (IHC)
detection, we tested 85 samples from our archive, all
molecularly characterized (IDH1/2, Histone H.3.3, BRAF,
TERT promoter and 1p/19q, 7p/EGFR, 10q copy numbers,
ATRX IHC, Fig. 7g). Again, GPR158 expression strongly
correlated with histological entities (Figs. 7g, h, i) being
highest in CNS cortex, followed by oligodendrogliomas,
whilst astrocytomas stained much weaker, but had still a
clearly visible ﬁne granular cytoplasmic stain. eGBM and
GBM showed no staining or only focal, patchy weak and
diffuse staining (no statistically signiﬁcant difference
between both groups). Small fragments of CNS cortex,
present in many samples, in particular of surgical aspirate,
served as internal technical control and were used to gen-
erate quantitative CNS grey matter expression data by
whole slide image analysis (Fig. 7h) [6], and also correlate
with TCGA and our own expression data (Figs. 6a, b, c). In
conclusion, we show here that GPR158 RNA and protein
expression correlate with distinct diagnostic glioma entities,
suggesting that GPR could represent a biomarker for stra-
tifying these tumours (Fig. 7i).
Lower miR-449a and higher GPR158 expression
correlates with longer survival of glioma patients
Finally we evaluated if miR-449a and GPR158 also have a
role as potential prognostic biomarker, i.e. correlate with
patient survival (Fig. 8). First we separated the 25 NHNN
patients of whom we had miR-449a expression values into
2 groups (above and below median) and found signiﬁcantly
better survival in the miR-449alow group (p= 0.004) (Fig.
8a). Next, we separated the 85 NHNN patients of whom we
had tissue stainings into two groups according to the
GPR158 stain score (above and below median), and found
that patients whose tumours expressed higher levels of
GPR158 survived longer (p < 0.05; Fig. 8b). Then we
accessed the TCGA repository, retrieved and quantiﬁed
GPR158 mRNA expression levels as per rsem (Supple-
mentary table 3), and assigned patients to 4 strata according
to their GPR158 rsem level (≤500 (Interval 1), >500 ≤ 1000
(Interval 2), >1000 ≤ 1500 (Interval 3) and >1500 (Interval
4)). There was a strong correlation between GPR158
expression level and survival across all tumours (p= 1.65E-
21; Fig. 8c). Patients with high GPR158 expression were
younger than those with low expression, consistent with
IDH mutant tumours occurring in younger patients are also
being associated with better survival. There is no signiﬁcant
association of GPR158 expression with gender (Fisher’s
exact test, p= 0.158-0.359, one interval vs. all other three
intervals, Supplementary table 3). To identify if GPR158
has a prognostic role within either IDH wild-type or IDH
mutant subgroups, we then grouped patients according to
the IDH mutation status. Although not reaching signiﬁcance
in the IDH mutant cohort, GPR158high tumours showed an
obvious tendency to longer survival (p= 0.057; Fig. 8d).
However, in the IDHwt eGBM subgroup, GPR158high
tumours showed no different survival from GPR158low
tumours, as only few patients were available in the
GPR158high group. We assessed the prognostic value of
A
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Numbers indicate reference to ﬁgures
Fig. 9 Target dependent effects of miR-449a on proliferation, differ-
entiation and glioma biology (a) in stemness—maintaining growth
conditions with EGF, FGF enriched serum-free medium, miR-449a—
mediated effects are predominantly exerted through CCND1 inhibi-
tion, thus reducing invasion and proliferation. For example, miR-
449ahigh Rb/p53 cells have low expression levels of Ccdn1, proliferate
and migrate slower, and have less self-renewal capacity. b in growth
conditions promoting neural phenotypes in vitro, such as FBS, For-
skolin, retinoic acid and in vivo experimental settings and humans
gliomas, miR-449a suppresses GPR158, reducing neural marker
expression, and is associated with higher glioma grade and shorter
survival. Numbers and letters provide a reference to ﬁgures in the text
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GPR158 in the four subtypes of GBM [4] and found sig-
niﬁcantly longer survival of GPR158high patients in the
proneural and neural groups (Fig. 8e and Supplementary
table 4), but not in the other two groups (Figs. 8g, h), and
there is no inﬂuence of CCND1 expression on survival
(Figs. 8j, k). In summary, in both the NHNN and the TCGA
glioma cohorts, we conﬁrmed that higher GPR158 tran-
script and protein expression levels correlate with better
survival, and patients with GPR158high IDHwt GBM
responded signiﬁcantly better to chemotherapy compared to
patients with GPR158low tumours (Fig. 6i, Supplementary
table 4).
Discussion
To identify differentially regulated genes and their targets in
gliomas, we used mouse models which develop two well-
deﬁned tumour phenotypes—gliomas (Pten/p53) or PNET
(Rb/p53)—with distinctive lineage, growth rate and inva-
siveness [6, 7]. In a microRNA screen, we identiﬁed miR-
449a as signiﬁcantly differentially regulated. miR-449a
belongs to the miR-34/449 family, and shares with miRNA-
34, 449b, and 449c seed sequences, secondary structures
[46], and downstream targets, including CCND1 and E2F
transcription factor 5 (E2F5) [27, 47–49]. To understand the
regulatory function of miR-449a in BTSC, we looked for
targets relevant for intrinsic brain tumours (Fig. 2). We
conﬁrmed and validated the known target CCND1 [20]
(encoding Cyclin D1) (Figs. 2e and 4a–f) and we identiﬁed
a new target, G-protein coupled receptor 158 (GPR158)
which is downregulated by miR-449a (Figs. 2c, e, f).
GPR158 was considered highly relevant, as it is most clo-
sely related to GABA receptors [28], is widely and strongly
expressed in the central nervous system and has a role in
cognition [50]. It is highly expressed in the CNS and low in
somatic organs https://www.proteinatlas.org/search/
GPR158, and it is also highly expressed in 'low grade
glioma' and in phaeochromocytoma/paraganglioma, a neu-
roendocrine neoplasm. Instead it is reduced in glioblastoma
and expressed at even lower levels in a malignant childhood
tumour, AT/RT (Supplementary Figure 3D, E). We show
here that miR-449a has target-dependent effects on cell
migration, proliferation and differentiation, mediated by
CCND1 or GPR158 (Fig. 9). miR-449a inhibits CCND1
under proliferative conditions in stem cell medium (serum
free, EGF, FGF supplemented), reducing proliferation and
migration (Figs. 3f, 4a–f and 5a). It also inhibits GPR158,
suppressing neural differentiation (Fig. 3f). Under these
conditions, however, GPR158 overexpression reverses
miR-449a—induced phenotypes (caused by CCND1 inhi-
bition) by promoting neural differentiation and apoptosis,
thus further reducing migration and proliferation (Figs. 4g-
s) and this creates a seemingly paradox result. This paradox
has been addressed by further studying the effects of miR-
449a and GPR158 in conditions facilitating neural differ-
entiation in vitro and in vivo. Under these conditions,
GPR158 induces neural, glial and neuronal phenotypes and
apoptosis (Figs. 4k-s and 5, Supplementary Figure 2) in
tumour spheres and cells and in allografts in vivo (Fig. 6).
This can be antagonised by miR-449 mimics (Fig. 5, Sup-
plementary Figure 2). GPR158 knockdown has opposite
effects, reducing neural differentiation, apoptosis and
increasing growth (Figs. 4k–o, and Supplementary Figure
2), whilst miR-449a antagomir restores a neural phenotype
(Fig. 5c4, Supplementary Figure 2). This antagonistic effect
between mir-449a and GPR158 was consistently found in
conditions promoting neural (FBS, Fig. 5), glial (LIF/
BMP2), and neuronal (retinoic acid/forskolin) phenotypes
(Supplementary Figure 2) in vitro, and in murine allografts
in vivo (Fig. 6).
In conclusion, the effects of miR-449a are modulated by
growth conditions and environment of BTSC (Fig. 9). Our
data raise the possibility that the effects of miR-449a may
be target-dependent, acting on CCND1 or GPR158 (Fig. 9).
miR-449a has an inhibitory effect on migration and inva-
sion in vitro in some cancer types [19, 20, 23] and Figs. 3d,
e). In vivo, miR-449a has a tumour suppressive effect in
some cancers, such as hepatocellular carcinoma, [16], or
lung cancer [18], but not in others, where an association
with cancer progression was found, such as breast [51] or
colorectal cancer [52]. A previous study on brain tumours
shows results similar to our in vitro data [17], whilst a
discrepancy of miR-449a correlation with brain tumour
grade is noted. In that study tumour types were not speciﬁed
and thus the results may not be directly comparable to our
cohort which used molecularly characterized and stratiﬁed
tumours. A yet different role of miR-449a has been iden-
tiﬁed in the developing neuroepithelium, where a transient
upregulation is associated with neural progenitor expansion
in the rat brain at embryonic day 10 [53] and suppression of
neural cell fate activates choroid plexus.
CCND1 can have context-depending roles in vitro and
in vivo: It is one of the major regulators of the cell-cycle
progression, can act as an oncogene, and aberrant expres-
sion is commonly seen in human cancers [54, 55]. In
keeping, in vitro under appropriate conditions CCND1
promotes proliferation and migration of BTSC (Figs. 4a–c,
5a and 9a), and is modulated by miR-449a expression, i.e.,
is higher in Pten/p53 mBTSC (miR-449alow) than in Rb/p53
mBTSC (miR-449ahigh) (Figs. 4c and 5a) and in miR-
449ahigh experimental tumours, Ccnd1 is downregulated
(Fig. 6t). Instead, in neural differentiation conditions Ccnd1
is downregulated (Fig. 5a) in keeping with overall reduction
of cell proliferation and increased neurogenesis [56, 57] and
differentiation into astrocytes [58]. This is consistent with
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our observation of higher expression of neural markers, and
of GPR158 and CCND1 in miR-449alow tumours develop-
ing from allografted Pten/p53 cells and from Rb/p53 cells
treated with miR-449a antagomir (Fig. 6). However, unlike
in many other cancers, CCND1 is not differentially
expressed in different grades and types of brain tumours
(Fig. 7e), and TCGA outcome data do not show a difference
in survival between patients with gliomas expressing low or
high CCND1 levels (Figs. 8j, k).
An important ﬁnding of our study is the inverse corre-
lation of miR-449a and GPR158 expression (p= 0.002, Fig.
7d). Of translational importance, miR-449a expression
correlates with tumour grade (Fig. 7c) and with poorer
survival (p= 0.004, Fig. 8a), and consistent with our
experimental data, GPR158 expression correlates with bet-
ter prognosis (Figs. 8b-i) and inversely with tumour grade
(Figs. 7e, i, h and 9b). Our results are discrepant to those of
a study on prostate cancer where increased expression of
GPR158 correlates with poorer survival [31]. This could be
related to the speciﬁc pathobiology of prostate cancer,
where enrichment of GPR158 expressing neuroendocrine
cells (thought to represent transdifferentiated prostate epi-
thelial cells) show more aggressive clinical behaviour and
thus are associated with poorer survival. In contrast,
expression of GPR158 and (pro-) neural markers is high in
low-grade gliomas and typically much lower in GBM.
Correlation of GPR158 expression levels to GBM, stratiﬁed
according to the molecular subtypes [4] further supports this
notion, as GPR158 expression is highest in the proneural
subtypes (a class that is enriched for IDH mutations and
PDGFR ampliﬁcations), and decreases in classical (enriched
for EGFR ampliﬁed and CDKN2A mutant tumours) and
mesenchymal subtypes, which are most commonly NF1
mutated (Supplementary Figure 3c). The neural subtype
surprisingly appears close to the classical and mesenchymal
type, and this could be ascribed to a possible “contamina-
tion” of the individual subclasses [59], or superimposed
effects of the tumour microenvironment [60]. In keeping
with these observations, the expression analysis with the
mouse Proﬁler PCR Array showed a signiﬁcant up-
regulation of Map2, Sox2, and Pdgfra (Fig. 4q) in Gpr158
expressing cells, and corresponding protein expression in
tumours developing from allografted cells in vivo (Fig. 6),
thus further strengthening the correlation of our experi-
mental data with clinical outcome data.
A further difference between prostate cancer and brain
tumours is that in the former, the C-terminal portion of
GPR158 is translocated to the nucleus whilst we did not
observe nuclear staining in CNS grey matter or in glioma
cells using a speciﬁc anti-GPR158 C-terminal antibody.
This discrepancy could be explained by different signalling
pathways relevant in prostate and brain tissues. A role of
GPR158 long non-coding antisense (AS) RNA in lung
cancer has recently been described, where high expression
of GPR158 AS1 correlates with poorer overall survival
[32]. In contrast, we show that GPR158 AS1 expression
level positively correlates with GPR158 mRNA level
(Supplementary Figure 3F). It has been shown previously
that antisense RNA can act both, enhancing and suppressing
and this is possibly related to differences in tissue speciﬁcity
[61, 62].
In conclusion, we identiﬁed through a phenotypic screen
the highly differentially regulated miR-449a, which targets
CCND1 and GPR158 and has target-dependent functions
(Fig. 9). It is highly expressed in a growth-promoting
environment in vitro, reducing proliferation and invasion. In
a neurogenic environment in vitro and in tumours in vivo it
inhibits neural phenotypes. We show that miR-449 directly
targets and downregulates CCND1, resulting in reduced
proliferation in vitro, and GPR158, antagonising neural
differentiation and apoptosis in glioma stem cells. High
miR-449a expression levels correlate with shorter survival,
whilst high GPR158 expression is associated experimen-
tally with neural phenotypes, cell differentiation and clini-
cally with lower glioma grades and better patient survival
and may serve as predictive biomarker. miR-449a could be
considered as druggable target, e.g., using antagomirs, and
GPR158, a member of a large family of receptors may be
targeted by pharmacological agents [63, 64], e.g., by sti-




All procedures performed on mice were according to
Institutional and UK Home Ofﬁce guidelines (Project
licenses 70-7428 and PA79953C0). The ARRIVE guide-
lines were followed as part of the institutional policy and
the licensing of the experiments. Mice carrying p53loxP/loxP,
RbloxP/loxP [65] or PtenloxP/loxP [66] transgenes were inter-
crossed resulting in co-deletion of Rb/p53 or Pten/p53 and
the ROSA26-lacZloxP/loxP reporter gene upon cre-mediated
recombination. Tumours were induced and BTSC derived
as described [7].
Microarray preparation, hybridization and data
analysis
Total RNA used for microarray was extracted from frozen
tumours using TRIzol [6]. miRNAs from 600ng of total
RNA were labelled with Hy3 or Hy5 ﬂuorophores accord-
ing to manufacturer’s protocol (miRCURY LNA micro-
RNA Hi-Power Labelling kit, Exiqon). Pair-wise RNA
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samples labelled with Hy3 or Hy5 dye were hybridized to
the miRCURY LNA microRNA Array 7 (Exiqon). Spike-
ins were used for array quality control. Microarrays slides
were scanned (G2565BA Agilent) and images quantiﬁed
using ImaGene 9 (Exiqon, Denmark). Background signals
were corrected using normexp method as described before
[67] with limma package on R. Expression validation by
quantitative real-time-PCR on a LightCycler 480 (Roche).
Ampliﬁcation curves were analysed using the Roche LC
software and normalized using ﬁve normalizers (Supple-
mentary table 1) to determine the −ΔΔCp value.
Validation of miRNA targets by Ago2 and biotin
double pull-down assay and luciferase assay
Direct miRNA-mRNA interaction was conﬁrmed by double
pull-down assay [35]. 8 × 106 mBTSC were transfected with
450 pmol of biotin-labelled miR-449a mimic (Exiqon). 10%
of the lysate was used as input RNA (Fraction 1), 90% for
double pull-down. The ﬁrst pull-down was on Argonaute
TISC-Catalytic Component 2 (Ago2) immunoprecipitation
with Protein G Dynabeads (75 μl; Invitrogen). For the sec-
ond pull-down, Dynabeads were incubated with Relay
Samples 2 and 3. RNA was eluted (miRCURY RNA Iso-
lation kit, Exiqon) to obtain Fractions 2 and 3. Ccnd1 and
Gpr158 was quantiﬁed by qRT-PCR. For the luciferase
assay, the 3′ UTR of Gpr158 (174 bp) containing wild-type
or mutant miR-449a-5p binding site were synthesized
commercially (GeneArt, Invitrogen). The 3′ UTR fragment
was inserted to pMIR-REPORT luciferase vector and
reporter assay was carried out 48 h post-transfection (Dual-
Light system, Applied Biosystems).
Cell proliferation, gap closure assay and migration
assays
Assays were performed on IncuCyte (Essen bioscience, US)
in 96 well plates. Proliferation: 1500 cells per well; Gap
closure assay: 75,000 cells per well, gap generation 24 h
post-seeding (wound maker, Essen bioscience) and mito-
mycin C (0.01 mg/ml) was added. Chemotactic migration
assay: 3000 cells seeded on a ClearView chemotaxis plate
(Essen bioscience). The bottom was ﬁlled with attractant
medium (40 ng/ml growth factor). Plates were scanned and
analysed using Incucyte Chemotaxis module. Collagen-
based invasion assay: 5000 cells per well in a U-bottom 96-
well plate in 100 μl of 20% (v/v) methylcellulose in culture
medium to form a sphere (24 h). Three hours after embed-
ding on ﬁbrillary bovine collagen (2.1 mg/ml), the spheres
were repeatedly imaged and quantiﬁed with Image J.
Knock-down or overexpression of miR-449a, CCND1
and GPR158
Murine brain tumour stem-like cells (mBTSCs) were
transfected with (i) LNA-miR-449a antagomir/inhibitors
(Exiqon), (ii) LNA-miR-449a mimics (Exiqon), (iii) mouse
Gpr158 siRNA (Life Technology Co.), (iv) CCND1 siRNA
(Cell Signaling), or (v) scramble controls using Viromer
Black (lipocalyx) according to the manufacturer’s protocol.
After 24 h, cells were used for proliferation, gap closure,
invasion, tumour-sphere, or differentiation assay; alter-
natively total RNA was extracted for transcript quantiﬁca-
tion after 48 h.
The lentiviral vector containing short hairpin RNA
(shRNA) for stable inhibition of human GPR158 and the
control vector were purchased from the UCL RNAi library.
Mouse Gpr158 cDNA clone in entry vector pENTR223.1
was purchased from DNASU, and cloned into pLX301
lentiviral vector. Lentivirus was produced in
HEK293T cells using Fugene according manufacturer’s
protocol (Promega). The human GPR158 expression vector
was a kind gift from Elizabeth Fini, University of Southern
California, Los Angeles [30].
Human tissue resources
The use of human tissue samples was licensed by the
NRES, University College London Hospitals NRES license
for using human tissue samples: Project ref 08/0077 (S.B.).
The storage of human tissue is licensed by the Human
Tissue Authority, UK, License #12054 to SB. hGBM-IC
were derived and cultured as described [68]. Glioma tissue
blocks and associated clinical and molecular information
were from the archives of the NHNN.
Extreme limiting dilution assay
Cells were plated in 96-well plates at 1, 2, 5, 10, 20, 50,
100, and 200 cells/well as described previously [69], and
cultured in 100 µl of serum-free medium per well as men-
tioned above. The percentage of wells with neurosphere
formation was determined 7 days post seeding. Stem cell
frequency was estimated using software available at http://
bioinf.wehi.edu.au/software/elda/ [39]. Further instructive
information can be found on this informal resource
http://www.biology-pages.info/L/LimitingDilution.html
Differentiation assay of cells overexpressing or
knockdown for GPR158 or for miR-449
Murine brain tumour stem cells of the Rb/p53 or Pten/p53
genotypes transduced with lentivirus expressing GPR158 or
GFP as control, containing puromycin a selection marker
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(4 weeks selection). 24 h after transfection/transduction
growth medium was exchanged with differentiation med-
ium containing DMEM/F12, 2% B27, 1% penicillin-strep-
tomycin, and supplemented with 3% FBS, or 10 uM RA
(Sigma, R2625) and 20 uM Forskolin (Abcam, ab120058)
for neuronal differentiation, or with 50 ng/ml LIF (Santa
Cruz, sc-4989) and 50 ng/ml BMP2 (Thermo Fisher,
PHC7145) for astrocytic differentiation [70]. After 48 h
differentiation cells were ﬁxed and stained for doublecortin
(DCX, ab18723, 1:800, Abcam) and GFAP (ab4674,
1:1000, Abcam), followed by secondary antibodies con-
jugated with Alexa dyes.
RT-qPCR and mouse neurogenesis proﬁler array
cDNA was synthesized using RevertAid RT kit (Thermo
Fisher Scientiﬁc Inc.). RT-qPCR was performed in triplicate
with SYBR Green Mastermix (Thermo Fisher Scientiﬁc
Inc.). The primers are listed in Supplementary table 5. Gene
expression was normalized against GAPDH levels and fold
changes were calculated using the 2-ΔΔCt method on
DataAssist 3.1 software (Thermo Fisher).
Caspase-3/7 activity assay
BTSCs or GBM primary cells with different expression
levels of Gpr158 (or GPR158) were lysed using lysis buffer
(#7018; Cell Signaling). Subsequently, 40 μg of the samples
was diluted to a ﬁnal volume of 150 μl with protease assay
buffer (20 mM HEPES (pH 7.5), 10% glycerol, and 2 mM
DTT), and supplemented with 20 μM caspase-3 preferred,
ﬂuorogenic substrate Ac-DEVD-AMC (#556449, BD
Pharmingen) for a 2-hour incubation 37 °C in a 96-well
plate as per the manufacturer’s instruction. Fluorescence
was determined (excitation, 360 nm; emission, 460 nm)
with a CytoFluor series 4000 plate reader (Applied Bio-
systems). Background ﬂuorescence was determined in wells
containing the assay buffer only.
Data acquisition of human gliomas
Human gliomas used in this study were from The Cancer
Genome Atlas (TCGA) or our institution as speciﬁed. The
TCGA cohort contained 281 LGG and 160 GBM cases, of
which the clinical information and RNA sequencing data
were downloaded from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/) in July 2015. IDH mutation and 1p/
19q codeletion status of LGG were taken from the dataset,
as reported by TCGA Research Network [71]. IDH muta-
tion status of GBM patients were determined by TCGA
Somatic Mutation File. A total of 431 patients were inclu-
ded in this study (Supplementary table 3). AT/RT expres-
sion data were retrieved from published datasets [12] and
analysed with GBM using HG133 microarray (GSE73038).
We retrieved all the molecular AT/RT (histologically ATRT
or PNET) and compared them with IDH wild-type GBM in
this data set, and analysed then using GEO2R (https://www.
ncbi.nlm.nih.gov/geo/info/geo2r.html).
IHC staining
All IHC stainings were carried out on immunostaining
instruments (Roche Ventana Discovery or LEICA Bond-
Max) following manufacturer’s guidelines. The following
antibodies were used in this study: anti-GPR158 (ab121388,
Abcam), anti-ATRX (HPA001906, Sigma), anti-IDH1R132H
(DIA H09, Dianova), anti-Olig2 (ab33427, abcam), anti-
Pdgfrα (ab15501, Abcam), anti-Sox2 (AB 5603, Chemicon)
and anti-DCX (ab18732, Abcam).
Image analysis
Histological slides were digitized on LEICA
SCN400 scanner (LEICA, Milton Keynes UK) at 40×
magniﬁcation. Digital image analysis was performed on
Deﬁniens Developer 2.4 (Munich, Germany). Image ana-
lysis was done as previously published [6].
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